I picked up another 1000 as well. Just too much value at this point and the divi is secure. I also own the preferred series A shares as well.
The reason this is important is that Raas inhibitor therapies could be complicated by therapies which control polassium levels. Here, the researchers show that such a confounding effect does not occur. THis then means that the product should have wider market acceptance. Sri
Abstract: 4140Maintenance of normal serum K+ with ZS-9 once daily in patients with CHF: subgroup analysis of a phase 3 multicenter, randomised, double-blind, placebo-controlled trial of patients with hyperkalaemia
M.A. El-Shahawy1, B. Singh2, H.S. Rasmussen3, P.T. Lavin4, A. Yang5, W. Qunibi6, 1Academic Medical Research Institute - Los Angeles - United States of America, 2Southwest Clinical Research Institute - Tempe - United States of America, 3ZS Pharma, Inc. - Coppell - United States of America, 4Boston Biostatistics Research Foundation - Framingham - United States of America, 5Xelay Acumen, Inc. - Belmont - United States of America, 6University of Texas Health Science Center at San Antonio - San Antonio - United States of America,
Heart failure, other
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 722
Hyperkalemia (HK) limits use of RAAS inhibitors (RAASi) in patients (pts) who derive the greatest cardiovascular or survival benefit, such as those with congestive heart failure (CHF), chronic kidney disease (CKD), or diabetes. ZS-9, a nonabsorbed cation exchanger designed to entrap potassium (K+) in the gut, significantly reduced serum K+ vs placebo (PBO) over 48 hr with excellent tolerability in pts with CKD and HK. We performed a predefined subset analysis in pts with CHF from a large phase 3 trial of ZS-9 for HK.
Methods: Pts (N=753) with K+ 5.0-6.5 mmol/L were randomized (1:1:1:1:1) to ZS-9 (1.25g, 2.5g, 5g or 10g) or PBO orally 3X daily for 48 hr (acute phase). At the end of this phase, pts with K+ 3.5-5.0 mmol/L (n=542) were re-randomized 1:1 to the same ZS-9 dose given acutely or PBO once daily (QD) for Day 3-15 (extended phase) (if they were on ZS-9 acutely), or re-randomized to 1.25g or 2.5g ZS-9 QD (if they were on PBO acutely). RAASi were kept constant during the study. We used unpaired t-test to compare serum K+ in the subset of pts with CHF treated with the highest ZS-9 dose (10g) vs PBO.
Results: Of 753 pts, 300 (40%) had CHF at baseline as determined by investigator, of whom 72% were on RAASi. Mean baseline K+ was 5.3 mmol/L in pts with CHF. Of the CHF pts, 204 entered the extended phase. Of these, 26 remained on 10g ZS-9 and 23 were switched to PBO. Their extended phase baseline K+ was comparable (4.4 vs 4.5 mmol/L) and similar to the overall group (4.5 [n=63] vs 4.4 [n=61] mmol/L). On Day 15, mean K+ (mmol/L) was 4.5 in CHF pts on 10g ZS-9 vs 5.0 in those switched to PBO (p=0.002; Fig. 1).
Conclusion: 10g ZS-9 once daily maintained mean serum K+
This stock should run up further, to about the 35 level. Why, their main competitor who is at about the same stage clinically has a market cap of about 750Millon (down from 1.2Billion) a few months ago. Do your own diligence but ZS-9 is a more selective drug.
Yup, agree completely. Still long and strong 8K shares. Great value here even IF, new P is not approved. Frankly, there is no rational reason why new P should not be approved, only irrational political reasons. Plenty of economic reasons, including FN jobs with the approval. New P wiol cost TGB considerably more than P (the previous plan). IMHO, new P will be approved.;..we all need to be patient and allow the process to proceed.
I think the move up had started. Lots of shares at the bid and ask and volume now accelerated though the day. Long 8K shares at average buy of 2.06 and feelin good. Sri
I believe it unlikely the shorts will hold their positions thru the weekend, we'll definately see some covering tomorrow.
If we can assume that valuation of the existing commercial portfolio goes across at 2.5 x currently projected (and downward adjusted) sales (very reasonable given the gross margins in play) along with a reasonable discounted value (incremental NPV) of their late stage pipeline, I arrive at an enterprise value of about 575M. Yahoo has them at 680 which cannot be correct. Nonetheless, this suggest a valuation, apart from any take out play of about 9.70 per share. I picked up a small block near the close today to test the waters.
Good luck all
Dear TGB followers...while have been in the doldrums for some time now and have seen many and varied excuses from TGB leadership, the 12 month copper chart continues to impress. We have seen steady increases and I heard this AM on finance radio that a breakout in copper prices may soon occur, in part due to money printing world wide. I still long 6000 shares.,
Probably correct. I think further momentum remains based on the recent news and there are still plenty of customers for guns with 10 or more round clips. I like this action.
News on Drudge report is that the white house is considering issuing executive orders and that our friend eric holder is assisting with reviews. Hey, if you can't get things done via congress, just issue a freeking executive order.....this is exactly why we have the second amendment, to prevent against tyranical leadership (dare I say leadership) like obama.